**Nevro Corp Announces Agreement for Acquisition by Globus Medical, Inc.****

**

On February 6, 2025, Nevro Corp. (NYSE: NVRO) revealed the signing of a pivotal Agreement and Plan of Merger with Globus Medical, Inc., a significant move that would see Nevro, a Delaware corporation, merging with and into Globus Medical. The terms of the agreement dictate that each outstanding share of Nevro common stock, aside from specific exceptions, will be converted into the right to receive $5.85 per share in cash upon the effective time of the merger.

Furthermore, all outstanding stock options and restricted stock units of Nevro will be automatically terminated and converted into cash amounts as part of the merger. The Merger Agreement entails customary conditions and covenants, including directives for Nevro to operate within its ordinary course of business and avoid certain activities without prior consent from Globus Medical.

The Board of Nevro has unanimously approved the Merger Agreement and recommended that stockholders adopt it. Moreover, a proxy statement will be prepared and filed with the SEC for stockholders’ approval at a special meeting. The Merger Agreement also lays out termination rights for both parties, including specific termination fees under various circumstances.

In a joint press release on February 6, 2025, both companies announced the execution of the Merger Agreement. Additionally, Nevro communicated the merger to its employees, suppliers, customers, faculty, and salespersons through various channels, ensuring transparency and clarity regarding the transaction. These communications, along with the press release, were submitted as exhibits in the SEC filing.

The acquisition aligns Nevro’s innovative products, particularly in spinal cord stimulation therapy, with Globus Medical’s comprehensive musculoskeletal solutions. The merger is anticipated to close in the second quarter of 2025 pending regulatory approvals and other customary conditions.

Both Nevro and Globus Medical underscored the potential of the partnership to enhance market penetration, increase growth opportunities, and provide superior healthcare outcomes. The companies are working diligently to ensure a seamless transition process for all stakeholders involved.

In conclusion, the acquisition of Nevro Corp. by Globus Medical, Inc. signifies a strategic step towards advancing medical technology solutions and expanding global reach within the healthcare industry.

This communication contains forward-looking statements based on current information available to Nevro as of the date hereof, and it disclaims any obligation to update these statements except as required by law. For more details on the transaction, investors are advised to refer to the filed exhibits and relevant documents for a comprehensive understanding of the merger process.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Nevro’s 8K filing here.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.